Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix Inc (BDSX) generates news across diagnostic testing developments, biopharmaceutical partnerships, and clinical validation studies in the lung disease diagnostics sector. As a precision medicine company operating a dual-platform business model, Biodesix's news coverage reflects both its commercial diagnostic testing activities and its research collaborations with pharmaceutical companies.
Diagnostic testing news for Biodesix typically includes updates on test adoption rates, new clinical evidence supporting the utility of its blood-based lung diagnostics, and expansions in insurance coverage or reimbursement policies. The company's Nodify and IQLung testing platforms serve healthcare providers making critical decisions about lung nodule management and cancer treatment, so clinical validation studies and real-world evidence publications represent material developments. Coverage also extends to regulatory milestones such as laboratory certifications and quality accreditations that enable the company to offer diagnostic services.
Biopharmaceutical development services news focuses on contract announcements with pharmaceutical companies, companion diagnostic collaborations, and clinical trial partnerships. These relationships can significantly impact the Development Services segment's revenue trajectory and demonstrate the company's scientific capabilities in biomarker discovery and diagnostic development. News about successful companion diagnostic approvals or clinical trial results using Biodesix's services validates the company's expertise in precision medicine applications.
Financial reporting represents a key news category, with quarterly earnings releases providing insights into test volume trends, revenue performance across the dual business segments, gross margin evolution, and progress toward profitability targets. Investor presentations and strategic updates outline management's vision for expanding market penetration in pulmonology and primary care settings. Technology and scientific news covers advancements in AI-based diagnostic algorithms, multi-omics analysis capabilities, and new biomarker discoveries that could inform future product development.
Biodesix (NASDAQ: BDSX) has announced interim results from the INSIGHT study, which involved approximately 2,000 NSCLC patients. The findings indicate that patients classified as HIC-Hot by the VeriStrat test lived 2-3 times longer than those classified as HIC-Cold. This suggests that the VeriStrat test can effectively guide immunotherapy treatment, improving survival rates. The study emphasizes the significance of immune classification in optimizing treatment strategies for advanced non-small cell lung cancer.
Biodesix, Inc. (BDSX) reported a 51% increase in lung diagnostic revenue to $4.5 million for Q3 2021, driven by Nodify nodule management tests and a growing sales force. Total revenue reached $6.5 million, with services revenue up 133% to $1.5 million. However, COVID-19 testing revenue fell 91% to $0.5 million. The gross margin improved to 58%, while operating expenses increased 46% to $16.9 million, resulting in a net loss of $11.5 million. The company launched a 72-hour liquid NGS test ahead of schedule and anticipates continued growth into 2022.
Biodesix, Inc. (NASDAQ: BDSX) announced its collaboration with Genentech to present three posters at the 36th Annual Society for Immunotherapy of Cancer (SITC) from Nov. 10-14, 2021. This research focuses on diagnostic tests for non-small cell lung cancer (NSCLC) patients undergoing immune checkpoint inhibitor therapy. CEO Scott Hutton highlighted the importance of quick, actionable test results for patient care. Key presentations include findings on the Primary Immune Response (PIR) test and Anti-PD-L1 Response Test (ART), emphasizing their potential in predicting treatment efficacy.
Biodesix, Inc. (NASDAQ: BDSX) announced that CEO Scott Hutton will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 4:30 PM ET. The event will be webcasts live and available for replay on the Company's website. Biodesix specializes in data-driven diagnostic solutions for lung disease, offering innovative non-invasive tests and leveraging AI for enhanced diagnostics. For more information about Biodesix, visit biodesix.com.
Biodesix, Inc. (BDSX) will announce its third quarter financial results for the period ending September 30, 2021, before market open on November 15, 2021. The company will host a conference call at 9:00 a.m. Eastern Time to discuss these results and provide a business update. Biodesix specializes in data-driven diagnostic solutions for lung disease, offering non-invasive tests like Nodify Lung® and Biodesix Lung Reflex® to support patient management. These initiatives potentially influence treatment timelines and decision-making processes in lung disease care.
Biodesix (NASDAQ: BDSX) announced new findings from its ORACLE study presented at the 2021 CHEST virtual conference, showcasing its Nodify XL2 blood test's ability to reduce unnecessary invasive procedures by up to 67% for patients with benign lung nodules. The study, which evaluated 331 patients, demonstrated significant reductions in biopsies and surgeries, enhancing patient management and overall peace of mind. The results further validate previous data from the PANOPTIC trial, indicating potential improvements in patient care and clinical outcomes.
Biodesix, Inc. (NASDAQ: BDSX) reported significant findings presented at the IASLC World Conference on Lung Cancer, emphasizing the role of genomic and proteomic testing in improving treatment outcomes for lung cancer patients.
Key studies included a blood-based proteomic test predicting survival in non-small cell lung cancer patients undergoing immunotherapy, and the rapid turnaround of a KRAS test that allows for expedited treatment decisions. CEO Scott Hutton highlighted the goal of enhancing patient outcomes while reducing healthcare costs.
Biodesix, a data-driven diagnostic solutions company, will present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on
The event will be available for live webcast and replay on the company's website. Biodesix specializes in lung disease diagnostics, with a portfolio that includes non-invasive tests and advanced AI integration, supporting rapid treatment decisions for lung cancer patients.
Biodesix, Inc. (BDSX) reported a strong second quarter for 2021, highlighting 180% growth in total revenue to $11.9 million, driven by a 109% increase in core lung diagnostic revenue. The company anticipates ongoing growth supported by its expanding sales force and emerging from the pandemic. Notably, COVID-19 testing revenue surged 345%, although a sequential decline was noted as vaccinations progressed. Despite a 38% rise in net loss to $11.4 million, Biodesix maintains a robust cash position of $56.3 million as of June 30, 2021.
FAQ
What is the current stock price of BIODESIX (BDSX)?
What is the market cap of BIODESIX (BDSX)?
